| Literature DB >> 23597243 |
Audrey de Jong, Nicolas Molinari, Sylvie de Lattre, Claudine Gniadek, Julie Carr, Mathieu Conseil, Marie-Pierre Susbielles, Boris Jung, Samir Jaber, Gérald Chanques.
Abstract
INTRODUCTION: A quality-improvement project was conducted to reduce severe pain and stress-related events while moving ICU-patients.Entities:
Mesh:
Year: 2013 PMID: 23597243 PMCID: PMC3672726 DOI: 10.1186/cc12683
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Study-design and quality method. This figure represents the quality-improvement process of pain and serious adverse events while moving ICU patients for turning and nursing care procedures. This 20-month process following the P-D-C-A steps was evaluated by four one-month studied phases separated by inter-study phases of four to six months. The present quality improvement process was the third quality process performed in the ICU regarding the management of sedation and analgesia. Consecutive improvement steps were followed according to the Plan-Do-Check-Adjust method for quality-improvement:
- P (Plan-step): Multidisciplinary ICU work group creation, choice of the studied procedure and design of the quality improvement process.
- D (Do-step): Beginning of the Nurse-Do study by a one-month baseline evaluation of pain management by nurse while moving the patients (studied Phase 1). Educational interventions for optimized pain management by nurse (Nurse-Do) started after the baseline studied phase.
- C (Check step): One-month evaluation (Check) of educational interventions (studied Phase 2).
- A (Adjust step): Adjustment of educational interventions implicating an increased multidisciplinary team collaboration, one-month evaluation (Check) of adjusted interventions (studied Phase 3).
- Consolidation step: one-month control audit of the PDCA quality improvement process (studied Phase 4).
Figure 2Flow chart of the study.
Characteristics of patients included in the four phases of the study.
| Phase 1 | Phase 2 | Phase 3 | Phase 4 |
|
|
| |
|---|---|---|---|---|---|---|---|
| Age (years), median (IQR) | 64 (54; 74) | 65 (49; 74) | 61 (49; 67) | 61 (51;69) | 0.87 | 0.10 | 0.24 |
| Female Sex, n (%) | 19 (36%) | 18 (38%) | 12 (28%) | 13 (26%) | 0.84 | 0.51 | 0.30 |
| SAPS II, median (IQR) | 41 (31; 54) | 38 (27; 53) | 34 (27; 41) | 37 (26; 53) | 0.64 | 0.07 | 0.57 |
| Surgical admission*, n (%) | 22 (42%) | 25 (53%) | 16 (37%) | 26 (52%) | 0.32 | 0.29 | 0.33 |
| Mechanical ventilation, n (%) | 24 (45%) | 21 (45%) | 13 (30%) | 22 (45%) | 0.95 | 0.13 | 0.90 |
| Sustained use of sedatives, n (%) | 22 (42%) | 15 (32%) | 9 (21%) | 14 (29%) | 0.32 | 0.03 | 0.15 |
| RASS level, median (IQR) | 0 (-3; 0) | 0 (-1; 0) | 0 (0; 0) | 0 (-1; 0) | 0.92 | 0.52 | 0.41 |
| Number of procedures evaluated per patient, median (IQR) | 2 (1; 4) | 2 (1; 3) | 3 (1; 5) | 3 (3; 3) | 0.39 | 0.38 | 0.24 |
IQR, Inter-Quartile-Range (25th to 75th percentiles); RASS, Richmond-Agitation-Sedation-Scale [29] from -5 (deep sedation) to +4 (combative agitation), a level of 0 defines an awake state of awareness without any agitation; SAPS II, Simplified-Acute-Physiology-Score II [31]. * Surgical patients all underwent abdominal surgery.
Figure 3Incidence of severe pain, serious adverse events and analgesia. This figure shows that the incidence of severe pain and serious adverse events (SAE) decreased across the quality improvement study while the proportion of given analgesia increased. The difference was significant for severe pain (P = 0.04 and 0.02), SAE (P < 0.001 and P < 0.01) and analgesia (P = 0.01 and P < 0.01) between Phase 1 (baseline) and Phases 3 and 4, respectively.
Factors associated with severe-pain determined by univariate and multivariate mixed-effects model analysis
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| All | Severe pain | Others |
| OR |
| |
| Phase 1, n (%) | 184 | 30 (49%) | 154 (27%) | |||
| Phase 2, n (%) | 129 | 12 (20%) | 117 (20%) | 0.22 | ||
| Phase 3, n (%) | 170 | 11 (18%) | 159 (28%) | 0.04 | 0.33 (0.11; 0.98) | 0.04 |
| Phase 4, n (%) | 149 | 8 (13%) | 141 (25%) | 0.03 | 0.30 (0.12; 0.95) | 0.02 |
| Age, median (IQR) | 63 (51; 71) | 64 (57; 76) | 63 (51; 71) | 0.16 | ||
| Female gender, n (%) | 186 (29%) | 17 (28%) | 169 (30%) | 0.94 | ||
| SAPS II, median (IQR) | 39 (29;41) | 39 (27;51) | 39 (30;51) | 0.48 | ||
| Surgical admission, n (%) | 219 (35%) | 25 (41%) | 194 (34%) | 0.23 | ||
| Intubation status, n (%) | 216 (34%) | 24 (39%) | 192 (34%) | 0.95 | ||
| Sustained use of sedatives, n (%) | 114 (18%) | 10 (16%) | 104 (18%) | 0.69 | ||
| RASS level, median (IQR) | 0 (-1; 0) | 0 (-1; 0) | 0 (-1; 0) | 0.31 | ||
CI, Confidence-Interval; IQR, Inter-Quartile-Range (25th to 75th percentiles); OR, Odd-Ratio; RASS, Richmond-Agitation-Sedation-Scale [29]; SAPS II, Simplified-Acute-Physiology-Score II [31]. In addition to studied phases, variables were selected in multivariate analysis if P-value was less than 0.20 in the univariate analysis, that is, were included in the final mixed-effect model: studied phases and age.
Factors associated with serious adverse events determined by univariate and multivariate mixed-effects model analysis
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| All procedures | Serious adverse events | Serious adverse events |
| OR |
| |
| Phase 1, n (%) | 184 (29%) | 68 (41%) | 116 (25%) | |||
| Phase 2, n (%) | 129 (20%) | 36 (22%) | 93 (20%) | 0.09 | ||
| Phase 3, n (%) | 170 (27%) | 29 (18%) | 141 (30%) | < 0.001 | 0.40 (0.23; 0.72) | < 0.01 |
| Phase 4, n (%) | 149 (24%) | 31 (19%) | 118 (25%) | < 0.01 | 0.53 (0.30; 0.92) | 0.03 |
| Age, median (IQR) | 63 (51; 71) | 64 (56; 75) | 62 (51; 70) | 0.09 | ||
| Female gender, n (%) | 186 (29%) | 44 (27%) | 142 (30%) | 0.44 | ||
| SAPS II, median (IQR) | 39 (29; 41) | 39 (31; 53) | 38 (28; 50) | 0.19 | ||
| Surgical admission, n (%) | 219 (35%) | 104 (63%) | 309 (66%) | 0.54 | ||
| Intubation status, n (%) | 216 (34%) | 79 (48%) | 137 (29%) | < 0.01 | 1.91 (1.28; 2.85) | < 0.01 |
| Sustained use of sedatives, n (%) | 114 (18%) | 38 (23%) | 76 (16%) | 0.17 | ||
| RASS level, median (IQR) | 0 (-1; 0) | 0 (-2; 0) | 0 (-1; 0) | 0.05 | ||
| Pain during moving | ||||||
| Moderate pain, n (%) | 160 (25%) | 41 (25%) | 119 (25%) | 0.81 | ||
| Severe pain, n (%) | 61 (10%) | 30 (18%) | 31 (7%) | < 0.001 | 2.74 (1.54; 4.89) | < 0.001 |
CI, Confidence interval; IQR, Interquartile Range (25th to 75th percentiles); OR, Odds ratio; RASS, Richmond Agitation-Sedation Scale [29]; SAPS II, Simplified Acute Physiology Score II [31]. In addition to studied phases, variables were selected in multivariate-analysis if P-value was less than 0.20 in the univariate analysis, that is, were included in the final mixed-effect model: studied phases, age, SAPS II, intubation status, sustained use of sedatives, RASS level and severe-pain events.
Incidence of serious adverse events during each phase of the study
| Phase 1 | Phase 2 | Phase 3 | Phase 4 |
|
|
| |
|---|---|---|---|---|---|---|---|
| Cardiac arrest, n (%) | 2 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | |||
| Arrhythmias, n (%) | 3 (2%) | 4 (3%) | 1 (1%) | 0 (0%) | |||
| Tachycardia, n (%) | 5 (3%) | 5 (4%) | 3 (2%) | 6 (4%) | |||
| Bradycardia, n (%) | 0 (0%) | 2 (2%) | 0 (0%) | 0 (0%) | |||
| Hypertension, n (%) | 14 (8%) | 2 (2%) | 6 (4%) | 11 (7%) | |||
| Hypotension, n (%) | 8 (4%) | 5 (4%) | 2 (1%) | 9 (6%) | |||
| Oxygen desaturation, n (%) | 19 (10%) | 15 (12%) | 8 (5%) | 6 (4%) | |||
| Bradypnea, n (%) | 2 (1%) | 6 (5%) | 0 (0%) | 0 (0%) | |||
| Ventilatory distress, n (%) | 24 (13%) | 13 (10%) | 15 (9%) | 2 (1%) | |||
| At least one event, n (%) | 68 (37%) | 36 (28%) | 29 (17%) | 31 (21%) | 0.09 | < 0.001 | 0.005 |
Statistical analysis was performed using a generalized linear mixed-effects model for repeated measures.
Proportion of pharmacological and non-pharmacological therapies used during each phase of the study
| Phase 1 | Phase 2 | Phase 3 | Phase 4 |
| |||
|---|---|---|---|---|---|---|---|
| Analgesics drugs, n (%) | |||||||
| WHO step 3 | 28 (15%) | 32 (25%) | 36 (21%) | 33 (22%) | 0.11 | 0.14 | 0.12 |
| WHO step 2: tramadol | 17 (9%) | 25 (19%) | 48 (28%) | 49 (33%) | 0.19 | 0.001 | < 0.001 |
| WHO step 1: acetaminophen | 29 (16%) | 23 (18%) | 44 (26%) | 36 (24%) | 0.72 | 0.23 | 0.17 |
| nefopam | 22 (12%) | 9 (7%) | 26 (15%) | 33 (22%) | 0.24 | 0.71 | 0.11 |
| At least one drug | 60 (33%) | 56 (43%) | 86 (51%) | 79 (53%) | 0.22 | 0.01 | 0.002 |
| Number of drugs per patient, mean (SD) | 0.52 (0.70) | 0.69 (0.77) | 0.91(0.85) | 1.01 (0.97) | 0.30 | 0.008 | < 0.001 |
| Non pharmacological therapies | |||||||
| Explication*, n (%) | 158 (87%) | 91(71%) | 140 (82%) | 0.01 | 0.62 | ND | |
| Massage, n (%) | 120 (66%) | 82 (64%) | 64 (38%) | 0.86 | < 0.001 | ND | |
| Standard music listening, n (%) | 12 (7%) | 10 (8%) | 4 (2%) | 0.08 | < 0.001 | ND | |
| Music therapy, n (%) | 0 (0%) | 5 (4%) | 0 (0%) | 0.99 | 1.00 | ND | |
| At least one therapy, n (%) | 160 (88%) | 98 (76%) | 142 (84%) | 0.06 | 0.54 | ND | |
| Number of therapies per patient, mean (SD) | 2 (1;3] | 3 (1;4] | 1 (1;2] | < 0.01 | 0.05 | ND | |
ND, not done (external audit of medical chart records); SD, Standard Deviation; WHO, World Health Organization. Analgesics were classified according to the WHO's pain relief ladder [55] used to treat pain. 1st step, non-opioid analgesics; 2nd step, minor opioids; 3rd step, major opioids. Non-pharmacological therapies were evaluated for the three first phases. Non-pharmacological therapies were not assessed during the post-intervention Phase 4 (see text). * Explication of the procedure process, insurance that pain will be taken into consideration, if any.